{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:20:19Z","timestamp":1790911219280,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Guidelines advise eculizumab prophylaxis for most kidney transplant recipients with atypical hemolytic uremic syndrome (aHUS). However, recurrence rates may be overestimated, and starting eculizumab at relapse (\u201crescue therapy\u201d) may prevent graft loss. Randomized controlled trials have not compared the efficacy, safety, and costs of different treatment strategies. We performed a comparative study, including a previously described Dutch cohort treated with rescue therapy and a UK cohort using eculizumab prophylaxis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>In the Netherlands, we selected all adult patients with aHUS who received a kidney transplant between 2010 and 2021 in the Radboud University Medical Center (n\u2005=\u200530) and enriched this cohort with 8 patients who received rescue therapy in other centers. The UK cohort included all adult patients with aHUS at moderate or high risk of recurrence, transplanted between 2013 and 2017 with prophylactic eculizumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>We included 38 Dutch patients and 35 UK patients. Characteristics were comparable, although the UK cohort included more patients with a complement factor H SCR20 mutation or hybrid gene (31% versus 5%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01), and more Dutch patients received living donor kidneys (66% versus 20%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Follow-up was comparable (the Dutch patients 70.8 mo, range, 10\u2013134; UK patients 55.4 mo, range, 2\u201395). Eighteen (47%) Dutch patients received rescue therapy. Death-censored graft survival was not significantly different (the Dutch patients 1 y, 3 y, and 6 y: 97.4%, 91.2%, and 87.1%, respectively; UK patients 1 y, 3 y, and 6 y: 97.1%, 88.2%, and 65.6%, respectively, log-rank <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.189).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>In a population characterized by low prevalence of \u201cvery high risk\u201d genes, who were predominantly transplanted using an endothelial protective regime, death-censored graft survival with eculizumab rescue therapy was not inferior to prophylaxis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000005135","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:03:05Z","timestamp":1721880185000},"page":"511-518","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Kidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy"],"prefix":"10.1097","volume":"109","author":[{"given":"Caroline","family":"Duineveld","sequence":"first","affiliation":[{"name":"Department of Nephrology, Radboud University Medical Center, Radboudumc Research Institute, Nijmegen, Gelderland, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Glover","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy N.","family":"Bouwmeester","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Amalia Children\u2019s Hospital, Radboud University Medical Center, Radboudumc Research Institute, Nijmegen, Gelderland, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.A.J.","family":"van de Kar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Amalia Children\u2019s Hospital, Radboud University Medical Center, Radboudumc Research Institute, Nijmegen, Gelderland, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Radboud University Medical Center, Radboudumc Research Institute, Nijmegen, Gelderland, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Sheerin","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"R1-20250219","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","article-title":"Anticomplement treatment in atypical and typical hemolytic uremic syndrome.","volume":"55","author":"Fakhouri","year":"2018","journal-title":"Semin Hematol"},{"key":"R2-20250219","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"R3-20250219","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference.","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"R4-20250219","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"R5-20250219","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome.","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R6-20250219","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ekir.2023.01.016","article-title":"Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation.","volume":"8","author":"Duineveld","year":"2023","journal-title":"Kidney Int Rep"},{"key":"R7-20250219","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.transproceed.2016.06.004","article-title":"Good outcomes in kidney transplantation with deceased donor with acute kidney injury: donor\u2019s age and not acute kidney injury predicts graft function.","volume":"48","author":"Si Nga","year":"2016","journal-title":"Transplant Proc"},{"key":"R8-20250219","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","article-title":"Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series.","volume":"70","author":"Duineveld","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R9-20250219","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/TP.0000000000004355","article-title":"Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome.","volume":"107","author":"Glover","year":"2023","journal-title":"Transplantation"},{"key":"R10-20250219","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.20233411S1800a","article-title":"Prospective evaluation of an improved eculizumab initial phase dosing regimen in adult patients with atypical hemolytic uremic syndrome.","volume":"34","author":"ter Avest","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"R11-20250219","article-title":"Proposal for individualized dosing of eculizumab in atypical hemolytic uremic syndrome: patient friendly and cost-effective.","author":"Ter Avest","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"R12-20250219","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"R13-20250219","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/tri.13022","article-title":"Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.","volume":"30","author":"Legendre","year":"2017","journal-title":"Transpl Int"},{"key":"R14-20250219","doi-asserted-by":"crossref","first-page":"e0188155","DOI":"10.1371\/journal.pone.0188155","article-title":"Long-term outcomes of the atypical hemolytic uremic syndrome after kidney transplantation treated with eculizumab as first choice.","volume":"12","author":"de Andrade","year":"2017","journal-title":"PLoS One"},{"key":"R15-20250219","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation.","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"key":"R16-20250219","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome\u2014the first year\u2019s experience.","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"key":"R17-20250219","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome.","volume":"4","author":"Siedlecki","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R18-20250219","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R19-20250219","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-20250219","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","article-title":"Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.","volume":"7","author":"Acosta-Medina","year":"2023","journal-title":"Blood Adv"},{"key":"R21-20250219","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","article-title":"A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.","volume":"119","author":"Roumenina","year":"2012","journal-title":"Blood"},{"key":"R22-20250219","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/ndt\/gfaa050","article-title":"Chronic thrombotic microangiopathy in patients with a C3 gain of function protein.","volume":"35","author":"Timmermans","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"R23-20250219","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/TP.0b013e31827e31c9","article-title":"Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation.","volume":"95","author":"de Vries","year":"2013","journal-title":"Transplantation"},{"key":"R24-20250219","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.ajkd.2017.08.005","article-title":"Kidney transplantation in patients with atypical hemolytic uremic syndrome: a therapeutic dilemma (or not)?","volume":"70","author":"Noris","year":"2017","journal-title":"Am J Kidney Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:01:14Z","timestamp":1739959274000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005135","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}